All you need to know about Qsymia
By John D Greene
Over the past twenty-five years, Obesity rates have spiraled to the level nearly 5 hundred million individuals worldwide. The United States leads the world, with a startling 31 % of the population being termed obese.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
Bio-pharmaceutical group, Vivus, has developed a product, in hope of rendering a solution to this pandemic problem. The Food and Drug Administration recently announced consent, for the once daily Medication, Qsymia, commonly known as the weight loss pill.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Forward thinking physicians and clinics nationwide have read these studies, and started programs to administer this weapon in the arsenal to fight obesity. The local provider in most areas, Equilibrium Weight Loss and Longevity Clinic, offers the drug in the form of extended-release capsules, as part of their medically supervised weight loss protocol. In the face of epidemic obesity, there is promise on the horizon.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
Bio-pharmaceutical group, Vivus, has developed a product, in hope of rendering a solution to this pandemic problem. The Food and Drug Administration recently announced consent, for the once daily Medication, Qsymia, commonly known as the weight loss pill.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Forward thinking physicians and clinics nationwide have read these studies, and started programs to administer this weapon in the arsenal to fight obesity. The local provider in most areas, Equilibrium Weight Loss and Longevity Clinic, offers the drug in the form of extended-release capsules, as part of their medically supervised weight loss protocol. In the face of epidemic obesity, there is promise on the horizon.
About the Author:
Are you looking to find out if Qsymia Capsules are already available around you? We all will have to get a doctors approval to get the Qsymia Available